[Use of intravenous polyclonal immunoglobulins in autoimmune and inflammatory disorders].
Initially used for the treatment of immunodeficiencies, intravenous immunoglobulins (IVIg) have increasingly been used as immunomodulatory agent in autoimmune and inflammatory disorders. The mode of action of IVIg is enigmatic, probably involving Fc-dependent and/or F(ab')2-dependent non-exclusive mechanisms of action. IVIg broadly interacts with the different components of the immune system: cytokines, complement, Fc receptors and several cell surface immunocompetent molecules. IVIg also has an impact on effector functions of immune cells. These mechanisms of action of IVIg reflect the importance of natural antibodies in the maintenance of immune homeostasis. We discuss here the recent advances in the understanding of immunoregulatory effects of IVIg, and we pointed out the need of new strategies to overcome the predicted increasing worldwide shortage of IVIg.
Graff-Dubois
Stéphanie
S
INSERM U 872, université René-Descartes (Paris-5), université Pierre-et-Marie-Curie (UPMC Paris-6) et équipe 16 (immunopathologie et immunointervention thérapeutique), centre de recherche des Cordeliers, 15 rue de l'Ecole-de-Médecine, 75006 Paris, France.
Sibéril
Sophie
S
Elluru
Sriramulu
S
Negi
Vir-Singh
VS
Delignat
Sandrine
S
Mouthon
Luc
L
Lacroix-Desmazes
Sébastien
S
Kazatchkine
Michel D
MD
Bayary
Jagadeesh
J
Kaveri
Srini V
SV
D001327:Autoimmune Diseases / Q000628:therapy*; D006801:Humans; D007141:Immunoglobulin Fc Fragments / Q000032:analysis; D016756:Immunoglobulins, Intravenous / Q000008:administration & dosage / Q000627:therapeutic use*; D007153:Immunologic Deficiency Syndromes / Q000628:therapy*; D007249:Inflammation / Q000628:therapy*
D007141:Immunoglobulin Fc Fragments; D016756:Immunoglobulins, Intravenous